NCT07069569View on ClinicalTrials.gov

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

May 1, 2027

Conditions
Chronic Hepatitis B
Interventions
DRUG

AHB-137

AHB-137 will be injected.

DRUG

Peg-IFN

Peg-IFN will be administered .

DRUG

Hepatitis B Vaccine

Hepatitis B vaccine will be administered.

Trial Locations (1)

Unknown

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Ausper Biopharma Co., Ltd.

INDUSTRY